Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

IMPORTANCE: The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or obesity is unknown. OBJECTIVE: To compare continued once-weekly treatment with subcutaneous semaglutide, 2.4 mg, with sw...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:JAMA
Hoofdauteurs: Rubino, Domenica, Abrahamsson, Niclas, Davies, Melanie, Hesse, Dan, Greenway, Frank L., Jensen, Camilla, Lingvay, Ildiko, Mosenzon, Ofri, Rosenstock, Julio, Rubio, Miguel A., Rudofsky, Gottfried, Tadayon, Sayeh, Wadden, Thomas A., Dicker, Dror
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Medical Association 2021
Onderwerpen:
Original Investigation
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7988425/
https://ncbi.nlm.nih.gov/pubmed/33755728
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2021.3224
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items